Agent for inhibiting visceral fat accumulation

ABSTRACT

To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant, or a fraction thereof containing the compound is used as an active ingredient.

TECHNICAL FIELD

The present invention relates to an agent for inhibiting visceral fataccumulation, which contains a compound having a lophenol skeleton as anactive ingredient, and to food or drink containing the same. Inparticular, the present invention relates to an agent for inhibitingvisceral fat accumulation, capable of reducing an amount of fataccumulated in abdominal cavity and preventing or ameliorating visceralfat type obesity which is considered to be a main factor of metabolicsyndrome, and to a physiologically functional food or drink, such asfood for specified health uses, containing the agent for inhibitingvisceral fat accumulation.

BACKGROUND ART

In recent years, a rapid increase in obesity involved in westernizationof lifestyle has become a serious problem. The obesity means a state inwhich excessive energy is accumulated owing to excessive ingestion ofcalorie and a decrease in calorie consumption caused by insufficientexercise or the like, and refers to “state where excessive amount of fattissues of body (body fat) is accumulated”. The obesity is indicated asa basis of onset of so-called lifestyle-related diseases such asdiabetes, hypertension, and hyperlipidemia and so forth.

The obesity exhibits a state of accumulation of excessive body fat and aphenomenon of a body weight increase. It is reported that, when rapidreduction of a body weight is conducted to ameliorate obesity, amountsof muscles playing a role in energy consumption also reduce togetherwith the fat, and in a case of elders, symptoms such as blood pressuredisorder and injury of articulatio coxae may occur (Non-patent Document1). In addition, for a case where reduction of the amount of fat isconducted without reducing a body weight, there is a report on exercisetherapy which is expected to exert an effect of improving muscle tissues(Non-patent Document 2). As described above, in recent years, there havebeen made attention on methods of ameliorating obesity by inhibitingaccumulation of body fat, not by reducing a body weight.

The fat tissues are grouped into subcutaneous fat which is accumulatedinside of a skin and visceral fat which is accumulated around visceralorgans in an abdominal cavity, which are collectively called “body fat”.It is known that obesity is classified into two types, subcutaneous fattype obesity involving accumulation of the subcutaneous fat and visceralfat type obesity involving accumulation of the visceral fat. Thevisceral fat accumulation particularly gives large effects on frequencyof onset of complications such as abnormal metabolism and cardiovasculardiseases in obesity and severity thereof.

Conventionally, it has been known that pathosis in which an individualis suffering from a combination of a plurality of lifestyle-relateddiseases, that is, “multiple risk factor syndrome”, significantlyincreases the risks of onset of arteriosclerotic disease, and conceptssuch as Syndrome X and metabolic syndrome have been proposed as riskfactors of arteriosclerotic disease. In order to evaluate comprehensiverisk and prevent of the onset of arteriosclerotic disease in thosemultiple risk factor syndromes, international integration of definitionof metabolic syndrome and diagnostic criteria therefore were conducted(Non-patent Document 3). In the diagnostic criteria for metabolicsyndrome which was proposed in Japan in April, 2005, a waist sizecorresponding to a visceral fat area of 100 cm² or more is adopted as anessential item instead of a body mass index (BMI) or a body fatpercentage which is generally used for indicating a level of obesity.Thus, the visceral fat accumulation has been recognized to be largelyinvolved in the cause of metabolic syndrome.

Exercise, diet, and behavior therapies are recommended as measures forreducing body fat. However, in a case where those therapies aredifficult to be carried out or continued, drug therapy or a surgery maybe conducted. At present, mazindol that is an anorectic is used as atherapeutic drug for obesity, and is prescribed basically for peoplesuffering from high levels of obesity which show BMI of 35 or more.However, mazindol not only gives side effects such as headache and drymouth, but has a large number of problems in that mazindol hascontraindication when severe dysfunctions are present in the kidney,liver, or pancreas, and cannot be administered for a long period of timebecause of its dependency, and the like.

Plant sterols such as β-sitosterol, campesterol, stigmasterol have beenknown to have a reducing effect on blood cholesterol by inhibitingabsorption of the cholesterol, and there is disclosed a lipidmetabolism-improving agent containing diglyceride and a plant sterol asactive ingredients(Patent Document 1). Further, there are disclosed ananti-obesity agent and a lipid metabolism-improving agent containing, asan active ingredient, a cholestenone compound which is synthesized byusing as a starting material the plant sterols such as β-sitosterol andcampesterol, or 4-cholesten-3-one (Patent Documents 2 to 5).

As typical plants belonging to the genus Aloe of the family Liliaceae,Aloe vera (Aloe barbadenisis Miller) and Aloe arborescen (Aloearborescen Miller var. natalensis Berger) have been known, and variouseffects of these plants have been reported. Specifically, it isdisclosed that an Aloe extract has a preventive or ameliorating effecton obesity (Patent Document 6). In addition, there are disclosed asupplement having an effect of reducing a body weight, which contains0.25% Aloe vera powder (Patent Document 7) and an essential oilcomposition for controlling a body weight, which contains Aloe vera(Patent Document 8), respectively. Further, it is reported thatadministration of a whole leaf of Aloe arborescens to a rat resulted ina significant decrease in a body weight depending on concentrations ofAloe arborescens (Non-patent Document 4 or 5).

[Patent Document 1] Japanese patent Laid-open NO. 2005-15425

[Patent Document 2] Japanese patent Laid-open NO. 07-165587

[Patent Document 3] Japanese patent Laid-open NO. 11-193296

[Patent Document 4] Japanese patent Laid-open NO. 2001-240544

[Patent Document 5] Japanese patent Laid-open NO. 05-170651

[Patent Document 6] Japanese patent Laid-open NO. 2000-319190

[Patent Document 7] New Zealand Patent No. 330439

[Patent Document 8] U.S. Pat. No. 6,280,751

[Non-patent Document 1] Journal of Applied Physiology, vol. 95, p.1728-1736, 2003

[Non-patent Document 2] Journal of Applied Physiology, vol. 99, p.1220-1225, 2005

[Non-patent Document 3] Adiposcience, vol. 2, p. 11-15, 2005

[Non-patent Document 4] Medical and Biology, 125(5), p. 189-194

[Non-patent Document 5] Bulletin of the Fujita Medical Society, 22(2),p. 153-157

DISCLOSURE OF THE INVENTION

Patent Document 1 does not describe an effect of administration of plantsterol alone, and does not describe or suggest at all the effect of theplant sterol on visceral fat.

In addition, there are disclosed that the 3-ketosteroid compounddisclosed in Patent Document 2, the cholestenone compound disclosed inPatent Document 3, and 24-alkyl-cholesten-3-one compounds such as24-methylcholest-5-en-3-one disclosed in Patent Document 4 have effectsof reducing a body weight, an amount of body fat, and an amount of bloodlipid. However, there is no description or suggestion that the compoundshave an effect of inhibiting visceral fat accumulation without affectingan amount of oral ingestion and an increase in body weight.

4-cholesten-3-one disclosed in Patent Document 5 is apparently differentfrom the active ingredient of the present invention. Specifically, theeffect of 4-cholesten-3-one described in Patent Document 5 is that, whena normal mouse ingests calories, the compound reduces, beyond necessity,fat components regarded to be within a normal range together with anexcessive amount of fat in an abdominal cavity. Therefore, the effect of4-cholesten-3-one is clearly different from the effect of the presentinvention, that is, an effect of effectively inhibiting only the fatcomponents accumulated around visceral organs in an amount more thanthat required in a case of an obese state or in a case where excessiveamounts of calories are ingested.

Further, there is disclosed that the agent for preventing andameliorating obesity of Patent Document 6 inhibits progression ofobesity involving an increase in body weight, and thus is effective formaintaining a standard body weight without a need for excessive dietrestriction. However, there is no description on the effect on the bodyfat, and no description about the effect of inhibiting visceral fataccumulation, which reduces the amount of visceral fat without reducinga body weight.

In addition, the active ingredient described in Patent Document 6 is anAloe extract. However, components related to the inhibition of theprogression of obesity involving an increase in body weight are notspecified at all. Therefore, it is difficult to predict presence of theeffect of inhibiting visceral fat accumulation, which reduces only thevisceral fat without reducing a body weight, that is an effect whichcannot be anticipated from the description in Patent Document 6.

Accordingly, with regard to an agent capable of selectively reducing thevisceral fat which is strongly related to onset of metabolic syndrome,or capable of preventing and inhibiting accumulation thereof, there hasbeen demanded a further development of a functional material which canbe ingested daily safely with pain as little as possible, and canefficiently reduce the visceral fat.

In view of the aforementioned circumstances, the inventors of thepresent invention have made extensive studies on an agent for inhibitingvisceral fat accumulation, which can prevent or ameliorate visceral fattype obesity that is considered to be a main cause of metabolicsyndrome. As a result, the inventors of the present invention have foundthat a compound having a lophenol skeleton has an effect of efficientlyreducing fat accumulated in an abdominal cavity. In addition, it wasfound that the compound has an effect of maintaining a standard bodyweight without reducing the body weight, and thus is useful forinhibiting progression of obesity without a need for excessive dietrestriction.

An object of the present invention is to provide an agent for inhibitingvisceral fat accumulation, which contains the compound having a lophenolskeleton as an active ingredient. In addition, it is another object ofthe present invention to provide a physiologically functional food ordrink such as food for specified health uses containing the agent forinhibiting visceral fat accumulation.

First invention of the present application to solve the aforementionedproblems is an agent for inhibiting visceral fat accumulation,containing a compound represented by the following general formula (1)as an active ingredient.

(In the formula, R1 represents an alkyl group, or an alkenyl grouphaving 1 or 2 double bonds, or a substituted alkyl or alkenyl grouphaving a hydroxyl group and/or a carbonyl group, which is straight orbranched chain having 5 to 16 carbon atoms, R2 and R3 each independentlyrepresent a hydrogen atom, an alkyl group or a substituted alkyl grouphaving 1 to 3 carbon atoms, and R4 forms C═O with the carbon atomconstituting the ring or represents —OH or —OCOCH₃.)

Further, the following 1) to 4) are preferred embodiments.

1) In the aforementioned compound, one of R2 and R3 is a hydrogen atom,the other is methyl group, and R4 is a hydroxyl group.

2) In the aforementioned 1), R1 is represented by any one of thefollowing formulas:

—CH₂—CH₂—CH(—CH₂—CH₃)—CH(CH₃)₂

—CH₂—CH₂—CH═C(CH₃)₂

—CH₂—CH═C(CH₃)—CH(CH₃)₂

—CH₂—CH₂—C(═CH—CH₃)—CH(CH₃)₂

—CH₂—CH₂—CH(R^(a))═C(CH₃)Rb

(wherein R^(a) and R^(b) is any of —H, —OH, or —CH₃)

—CH₂—CH₂—CH(R^(c))—CH(CH₃)Rd

(wherein R^(c) and R^(d) is any of —H, —OH, or —CH₃)

3) The aforementioned compound described in 2) is selected from thegroup consisting of 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-oland 4-methylstigmast-7-en-3-ol.

4) The aforementioned compound described in 1) to 3) is contained in anamount of at least 0.001% by dry mass.

Second invention of the present application to solve the aforementionedproblems is an agent for inhibiting visceral fat accumulation,containing an organic solvent extract or a hot water extract of aLiliaceae plant, or a fraction thereof, which contains a compoundrepresented by the following general formula (1), and in which theorganic solvent extract or the hot water extract of the aforementionedLiliaceae plant, or the fraction thereof contains as an activeingredient a composition containing at least 0.001% by dry mass of thecompound represented by the following general formula (1).

(In the formula, R1 represents an alkyl group, or an alkenyl grouphaving 1 or 2 double bonds, or a substituted alkyl or alkenyl grouphaving a hydroxyl group and/or a carbonyl group, which is straight orbranched chain having 5 to 16 carbon atoms, R2 and R3 each independentlyrepresent a hydrogen atom, an alkyl group or a substituted alkyl grouphaving 1 to 3 carbon atoms, and R4 forms C═O with the carbon atomconstituting the ring or represents —OH or —OCOCH₃.)

Further, the following 5) to 7) are preferred embodiments.

5) In the aforementioned compound, one of R2 and R3 is a hydrogen atom,the other is methyl group, and R4 is a hydroxyl group.

6) In the aforementioned 5), R1 is represented by any one of thefollowing formulas:

—CH₂—CH₂—CH(—CH₂—CH₃)—CH(CH₃)₂

—CH₂—CH₂—CH═C(CH₃)₂

—CH₂—CH═C(CH₃)—CH(CH₃)₂

—CH₂—CH₂—C(═CH—CH₃)—CH(CH₃)₂

—CH₂—CH₂—CH(R^(a))═C(CH₃)Rb

(wherein R^(a) and R^(b) is any of —H, —OH, or —CH₃)

—CH₂—CH₂—CH(R^(c))—CH(CH₃)Rd

(wherein R^(c) and R^(d) is any of —H, —OH, or —CH₃)

7) The aforementioned compound described in 6) is selected from thegroup consisting of 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-oland 4-methylstigmast-7-en-3-ol.

Third invention of the present application to solve the aforementionedproblems is a food or drink containing the aforementioned agent forinhibiting visceral fat accumulation according to the first or secondinvention.

In addition, the following 8) is a preferred embodiment.

8) The food or drink contains the compound represented by theaforementioned general formula (1) in an amount of 0.0001% by mass ormore.

Fourth invention of the present application to solve the aforementionedproblems is use of a compound represented by the aforementioned generalformula (1), or an organic solvent extract or hot water extract of aLiliaceae plant, or a fraction thereof which contains at least 0.001% bydry mass of the compound for production of an agent for inhibitingvisceral fat accumulation.

Fifth invention of the present application to solve the aforementionedproblems is a method of inhibiting visceral fat accumulation, whichcomprises administering a compound represented by the aforementionedgeneral formula (1), or an organic solvent extract or hot water extractof a Liliaceae plant, or a fraction thereof, which contains at least0.001% by dry mass of the compound to a subject whose the visceral fataccumulation is to be inhibited.

In the aforementioned use and method of the present invention, preferredembodiments of the compound represented by the aforementioned generalformula (1) are the same as that of the second invention of the presentapplication.

The agent for inhibiting visceral fat accumulation of the presentinvention and the food or drink containing the same can be administeredor ingested safely, and have an effect of effectively inhibiting thevisceral fat accumulation. In addition, the active ingredient of theagent for inhibiting visceral fat accumulation of the present inventioncan be ingested safely from experience, and can easily be produced fromavailable Liliaceae plants such as Aloe vera (Aloe barbadensis Miller).

BEST MODE FOR CARRYING OUT THE INVENTION

Next, preferred embodiments of the present invention are described indetail. However, the present invention is not limited to the followingpreferable embodiments, and modifications can be freely made within thescope of the present invention. Note that, percentage as used hereinindicates percentage by mass unless otherwise specified.

In the present invention, the effect of inhibiting visceral fataccumulation means an effect of reducing an amount of fat accumulated inan abdominal cavity. Therefore, the effect of inhibiting visceral fataccumulation can be evaluated by measuring an amount of fat in anabdominal cavity, for example, a weight of mesenteric fat.

The compound used as the active ingredient of the agent for inhibitingvisceral fat accumulation of the present invention (hereinafter, alsoreferred to as “agent of the present invention”) is the compound havingthe structure represented by the aforementioned general formula (1), andany derivatives and the like of the compound are included as the activeingredient so long as they each are a compound having the effect ofinhibiting visceral fat accumulation (hereinafter, also referred to as“compound of the present invention”).

It is most preferred that a purity of the compound of the presentinvention which is used as the active ingredient of the agent forinhibiting visceral fat accumulation of the present invention is 100%.However, the purity can be appropriately set within a range where thecompound exerts the effect of inhibiting visceral fat accumulation.

In addition, the composition which is used as an active ingredient ofthe agent for inhibiting visceral fat accumulation of the presentinvention (hereinafter, also referred to as “composition of the presentinvention”) is an extract of a Liliaceae plant or a fraction thereof,which contains the aforementioned compound in an amount of at least0.001% by dry mass, preferably 0.01% by dry mass or more, and morepreferably 0.1% by dry mass or more. The upper limit of the content ofthe compound of the present invention is, but not particularly limitedto, and it may be preferably 10% by dry mass, 50% by dry mass, 70% bydry mass, or 90% by dry mass, for example.

“Dry mass” as used in the present invention means a mass measured aftera compound is dried by the drying method defined by “Drying Loss Test”that is a general test method as described in Japanese Pharmacopoeia,14th Revision, (Mar. 30, 2001, Japan Ministry of Health, Labor andWelfare, Ministerial Notification No. 111). For example, the mass of thecompound of the present invention can be determined in such a mannerthat: about 1 g of the compound of the present invention is measuredoff, and dried at 105° C. for 4 hours; and the resultant is cooled bystanding in a desiccator; and the mass of the compound is weighed with ascale.

In the aforementioned general formula (1), R1 represents an alkyl groupor an alkenyl group having 1 or 2 double bonds, which is straight orbranched chain having 5 to 16 carbon atoms. Note that the aforementionedalkyl group and alkenyl group may be a substituted alkyl and alkenylgroup having a hydroxyl group and/or a carbonyl group, respectively. R2and R3 each independently represent a hydrogen atom, an alkyl group or asubstituted alkyl group having 1 to 3 carbon atoms, and R4 forms C═Owith the carbon atom constituting the ring or represents —OH or —OCOCH₃.As the aforementioned alkyl group having 1 to 3 carbon atoms, methylgroup, ethyl group and so forth are preferred, and methyl group isparticularly preferred.

The aforementioned R1 is preferably any one of the groups represented bythe following formulas.

—CH₂—CH₂—CH(—CH₂—CH₃)—CH(CH₃)₂  (i)

—CH₂—CH₂—CH═C(CH₃)₂  (ii)

—CH₂—CH═C(CH₃)—CH(CH₃)₂  (iii)

—CH₂—CH₂—C(═CH—CH₃)—CH(CH₃)₂  (iv)

—CH₂—CH₂—CH(R^(a))═C(CH₃)R^(b)  (v)

(wherein R^(a) and R^(b) is any of —H, —OH, or —CH₃)

—CH₂—CH₂—CH(R^(c))—CH(CH₃)Rd  (vi)

(wherein R^(c) and R^(d) is any of —H, —OH, or —CH₃)

Further, it is preferred that one of R2 or R3 is a hydrogen atom, andthe other is a methyl group. Further, it is preferred that R4 is ahydroxyl group.

The most preferred compounds as the aforementioned compound are thoserepresented by the following formulas, 4-methylcholest-7-en-3-ol(formula (2)), 4-methylergost-7-en-3-ol (formula (3)) and4-methylstigmast-7-en-3-ol (formula (4)).

That is, 4-methylcholest-7-en-3-ol is a compound represented by theaforementioned general formula (1) wherein one of R2 and R3 is ahydrogen atom, the other is methyl group, R4 is a hydroxyl group, and R1is a group represented by the aforementioned formula (vi) (R^(c)represents —H, and R^(d) represents —CH₃). Further,4-methylergost-7-en-3-o¹ is a compound represented by the aforementionedgeneral formula (1) wherein one of R2 and R3 is a hydrogen atom, theother is methyl group, R4 is a hydroxyl group, and R1 is a grouprepresented by the aforementioned formula (vi) (R^(c) and R^(d) bothrepresent —CH₃)— Further, 4-methylstigmast-7-en-3-ol is a compoundrepresented by the aforementioned general formula (1) wherein one of R2and R3 is a hydrogen atom, the other is methyl group, R4 is a hydroxylgroup, and R1 is a group represented by the aforementioned formula (i).

The agent, food or drink of the present invention may contain one typeor two or more arbitrary types of the aforementioned compounds.

It is known that lophenol is contained in plants, and the compound ofthe present invention can be produced according to the known method forproducing lophenol (Yamada A., “Experimental Methods of Biochemistry”,Vol. 24, Experimental Methods for Fat and Lipid Metabolism, p. 174,Gakkai Shuppan Center, 1989). The compound of the present invention canbe obtained by, for example, extracting the compound from a plantcontaining the same using a method such as extraction with an organicsolvent or extraction with hot water and purifying the obtained extract.In the present invention, although the compound of the present inventionmay be purified, a composition such as a plant extract or a fractionthereof may also be used so long as it contains an effective amount ofthe compound.

The compound of the present invention or the composition containing thesame can be produced in such a manner that, for example: from a plantbelonging to the family Liliaceae, a part or crushed product thereofcontaining the compound of the present invention, a fraction containingthe compound is extracted with an organic solvent or hot water andconcentrated.

Examples of the aforementioned plant belonging to the family Liliaceaeinclude plants belonging to the genus Aloe or Allium. Examples of theplants of the genus Aloe include Aloe vera (Aloe barbadensis Miller),Aloe ferox Miller, Aloe africana Miller, Aloe arborescen Miller var.natalensis Berger, Aloe spicata Baker and so forth. In the production ofthe compound of the present invention or a composition containing thesame, although the whole of the aforementioned plant may be used, it ispreferable to use mesophyll (clear gel portion) thereof. Such a plant ora part thereof is disrupted preferably by using a homogenizer or thelike and thereby liquefied, and the compound of the present invention ora composition containing the same is extracted from the disruptionproduct by using an organic solvent or hot water. Examples of theorganic solvent include alcohols such as methanol, ethanol and butanol;esters such as methyl acetate, ethyl acetate, propyl acetate and butylacetate; ketones such as acetone and methyl isobutyl ketone; ethers suchas diethyl ether and petroleum ether; hydrocarbons such as hexane,cyclohexane, toluene and benzene; halogenated hydrocarbons such ascarbon tetrachloride, dichloromethane and chloroform; heterocycliccompounds such as pyridine; glycols such as ethylene glycol; polyhydricalcohols such as polyethylene glycol; nitrile solvents such asacetonitrile, mixtures of these solvents and so forth. Further, thesesolvents may be anhydrous or hydrous. Among these solvents, ethylacetate/butanol mixture (3:1) and chloroform/methanol mixture (2:1) areparticularly preferred.

As the extraction method, a method used for usual extraction of a plantcomponent can be used. Usually used is, for example, a method ofrefluxing 1 to 300 parts by mass of an organic solvent with 1 part bymass of fresh plant or dried plant with heating at a temperature belowthe boiling point of the solvent and stirring or shaking, or a method ofperforming extraction by ultrasonication at room temperature. Byisolating insoluble matters from the extraction liquor using a suitablemethod such as filtration or centrifugation, a crude extract can beobtained.

The crude extract can be purified by various types of chromatographysuch as normal or reverse phase silica gel column chromatography. When agradient of chloroform/methanol mixture is used in normal phase silicagel column chromatography as an elution solvent, the compound of thepresent invention is eluted with a mixing ratio ofchloroform:methanol=about 25:1. Further, when a hexane/ethyl acetatemixture (4:1) is used in reverse phase silica gel column chromatographyas an elution solvent, the compound of the present invention is elutedin a fraction eluted at an early stage. The obtained fraction can befurther purified by HPLC or the like.

Further, the compound used for the present invention may also beproduced by a chemical synthesis method or a biological or an enzymaticmethod using microorganisms, enzymes or the like.

Whether a compound or a composition containing the same obtained asdescribed above is or contains the compound of the present invention canbe confirmed by, for example, mass spectrometry (MS), nuclear magneticresonance (NMR) spectroscopy or the like.

The compound of the present invention has an effect of inhibitingvisceral fat accumulation, and thus can prevent the visceral fat typeobesity. Therefore, the compound of the present invention can be used asan active ingredient of an agent or food or drink for inhibitingvisceral fat accumulation.

Furthermore, because leaf-skin of Aloe vera contains barbaloin andaloe-emodin which have a laxative action, the components have beenconsidered to be unfavorable for use in an agent or food or drink whichis not expected to have the laxative action. Therefore, it is preferablethat the composition containing the compound of the present invention donot contain the aforementioned components. In addition, the mesophyll ofAloe vera or a crushed product thereof can be used as an activeingredient of the agent for inhibiting visceral fat accumulation.

The compound of the present invention has an effect of inhibitingvisceral fat accumulation, and thus can prevent the visceral fat typeobesity. Therefore, the compound of the present invention per se can beused as an active ingredient of the agent for inhibiting visceral fataccumulation of the present invention and food or drink comprising theagent.

Further, an organic solvent extract or a hot water extract of a plant ora fraction thereof containing the compound of the present invention(hereinafter referred to as “extract etc.”) may also be used as anactive ingredient of the agent or food or drink. In this case, theaforementioned extract etc. to be contained in the agent preferablycontains at least 0.001% by dry mass, more preferably 0.01 to 1% by drymass, particularly preferably 0.05 to 1% by dry mass, of the compound ofthe present invention. Further, the aforementioned extract etc. to becontained in the food or drink preferably contains at least 0.0001% bydry mass, more preferably 0.001 to 1% by dry mass, particularlypreferably 0.005 to 1% by dry mass, of the compound of the presentinvention. The aforementioned extract etc. may contain two or more typesof the compound of the present invention. Further, the aforementionedextract etc. may be a solution, or can also be lyophilized orspray-dried in a conventional manner and stored or used as powder.

As the agent for inhibiting visceral fat accumulation of the presentinvention, the compound of the present invention or a compositioncontaining the same per se, or the compound of the present invention ora composition containing the same combined with a pharmaceuticallyacceptable carrier can be orally or parenterally administered to amammal including human. In the agent for inhibiting visceral fataccumulation of the present invention, the compound of the presentinvention may be a pharmaceutically acceptable salt. Examples of thepharmaceutically acceptable salt include both metal salts (inorganicsalts) and organic salts including, for example, those listed in“Remington's Pharmaceutical Sciences,” 17th edition, p. 1418, 1985.Specific examples thereof include, but not limited to, inorganic acidsalts such as hydrochloride, sulfate, phosphate, diphosphate andhydrobromate, and organic acid salts such as malate, maleate, fumarate,tartarate, succinate, citrate, acetate, lactate, methanesulfonate,p-toluenesulfonate, pamoate, salicylate and stearate. Furthermore, thesalt may be a salt with a metal such as sodium, potassium, calcium,magnesium and aluminum or a salt with an amino acid such as lysine.Furthermore, solvates such as hydrates of the aforementioned compound orpharmaceutically acceptable salts thereof also fall within the scope ofthe present invention.

Dosage form of the agent for inhibiting visceral fat accumulation of thepresent invention is not particularly limited and can be suitablyselected depending on the therapeutic purpose. Specific examples thereofinclude tablet, pill, powder, solution, suspension, emulsion, granules,capsule, syrup, suppository, injection, ointment, patch, eye drop, nasaldrop and so forth. For the preparation, additives generally used inusual preventive agents for inhibiting visceral fat accumulation aspharmaceutical carriers such as excipients, binders, disintegratingagents, lubricants, stabilizers, flavoring agents, diluents, surfactantsand solvents for injection and so forth can be used. Furthermore, solong as the effect of the present invention is not degraded, thecompound of the present invention or the extract etc. containing thesame can be used in combination with other agents having an effect ofinhibiting visceral fat accumulation.

Although the amount of the compound of the present invention or theextract etc. containing the same contained in the agent for inhibitingvisceral fat accumulation of the present invention is not particularlylimited and can be suitably selected, the amount may be, for example, atleast 0.001% by mass, preferably 0.01 to 1% by mass, particularlypreferably 0.05 to 1% by mass, in terms of the amount of the compound ofthe present invention.

The agent for inhibiting visceral fat accumulation of the presentinvention has the effect of inhibiting visceral fat accumulation, andthus can prevent the visceral fat type obesity. The visceral fat typeobesity generally refers to a state where an area of visceral fat is 100cm² or more, and according to the diagnostic criteria for metabolicsyndrome, refers to a case where a Japanese male has a waist size of 85cm or more, or a Japanese female has a waist size of 90 cm or more(Internal Medicine, vol. 94, p. 188-203, 2005). In addition, the agentfor inhibiting visceral fat accumulation of the present invention ispreferably used for treatment of a patient who has a larger amount ofthe visceral fat accumulated than a healthy person.

In addition, the agent for inhibiting visceral fat accumulation of thepresent invention can ameliorate or prevent diseases, complications andthe like caused by the visceral fat accumulation, such as abnormal lipidmetabolism and cardiovascular diseases, and can also reduce risks ofthose diseases, complications and the like. Examples of the variousdiseases caused by the visceral fat accumulation include obesity, inparticular, visceral fat type obesity, hyperlipidemia, diabetes,hypertension and arteriosclerosis. Examples of the complications causedby those diseases include: diabetic retinopathy, nephropathy,neuropathy, and diabetic gangrene caused by diabetes; cerebral stroke,nephrosclerosis, and renal failure caused by hypertension; and cerebralstroke, cerebral infarction, cardiovascular diseases such as anginapectoris and cardiac infarction, and nephropathy such as uremia,nephrosclerosis, and renal failure caused by arteriosclerosis disease.In addition, the inventors of the present invention have found that thecompound of the present invention has an effect of amelioratinghyperglycemia by reducing a hemoglobin Alc level (WO 2005/094838). It ispreferred that the diseases to which the agent for inhibiting visceralfat accumulation of the present invention is applied are not accompaniedwith a state where the hemoglobin Alc level is higher than that of ahealthy person.

Further, the agent for inhibiting visceral fat accumulation of thepresent invention is useful for preventing onset of metabolic syndrome.The effect of the agent of inhibiting or reducing the accumulation ofthe visceral fat as described above is extremely effective forpreventing the onset of metabolic syndrome and metabolicsyndrome-related arteriosclerotic diseases, and lifestyle-relateddiseases indicated as risk factors thereof, such as diabetes,hypertension, and hyperlipidemia, and complications associated withthose diseases. Furthermore, “metabolic syndrome” as used in the presentinvention refers to a state where arteriosclerosis is easily occurredand where there is a combination of symptoms regarded as risk factors ofpathosis of the multiple risk factor syndrome, such as hyperinsulinemia,abnormal glucose tolerance or hyperglycemia, abnormal lipid metabolism,hyperlipidemia (hypertriglyceridemia and hypo-HDL-cholesterolemia),hypertension, obesity, and visceral fat accumulation.

The administration time of the agent of the present invention is notparticularly limited and can be suitably selected according to themethod for treating an objective disease. Furthermore, theadministration route is preferably determined depending on the dosageform, age, sex and other conditions of patients, severity of symptoms ofpatients and so forth. The dose of the agent of the present invention issuitably selected depending on the dosing regimen, age and sex ofpatients, severity of disease, other conditions of patients and soforth. The amount of the compound of the present invention as an activeingredient is usually selected from the range of, preferably 0.001 to 50mg/kg/day, more preferably 0.01 to 1 mg/kg/day, as a tentative dose.Furthermore, when an extract etc. containing the compound of the presentinvention is used, the dry weight of the extract etc. is selected fromthe range of, preferably 0.1 to 1000 mg/kg/day, more preferably 1 to 100mg/kg/day, as a tentative amount. In any case, the dose can be ingestedin a day, once or several times as divided portions.

The compound of the present invention or the composition containing thesame can be added to food or drink (a drink or a food) to produce a foodor drink having an effect of inhibiting visceral fat accumulation. Theform and property of the food or drink are not particularly limited solong as the effect of the active ingredient is not degraded, and thefood or drink can be orally ingested, and it can be produced in aconventional manner by using raw materials usually used for food ordrink except that the aforementioned active ingredient is added. Theamount of the compound of the present invention or the extract etc.containing the same contained in the food or drink of the presentinvention is not particularly limited and can be suitably selected. Forexample, the compound of the present invention or the extract etc.containing the same is contained in the food or drink in an amount of atleast 0.0001% by mass, preferably 0.001 to 1% by mass, particularlypreferably 0.005 to 1% by mass, in terms of the amount of the compoundof the present invention.

The food or drink of the present invention can be applied to varioususes which utilize the effect of reducing visceral fat. For example, itcan be used as food or drink suitable for a person who began to worryabout their waist size, food or drink suitable for a person who began toworry about blood lipid, and food or drink useful for reducing orremoving risk factors of metabolic syndrome and the like.

“Inhibition of visceral fat accumulation” as used in relation to thefood or drink of the present invention means that various kinds ofadverse effects on health induced by the visceral fat accumulation areameliorated or prevented.

“Amelioration of visceral fat type obesity”, “prevention of visceral fattype obesity”, “reduction of visceral fat”, “prevention of visceral fataccumulation”, and the like can also be exemplified as the same meaningas the aforementioned term “inhibition of visceral fat accumulation” inthe present invention.

In addition, the food or drink of the present invention is useful forameliorating or preventing diseases caused by the visceral fataccumulation, such as abnormal lipid metabolism, cardiovasculardiseases, and the like typified by hyperlipidemia. The food or drink ofthe present invention can also be used for preventing the onset ofvisceral fat type obesity and metabolic syndrome, and the like. Further,the food or drink of the present invention can treat or prevent variousdiseases, complications, and the like caused by the visceral fataccumulation, and can reduce the risks of those diseases, complicationsand the like, as mentioned above for the agent of the present invention.

The food or drink of the present invention is preferably marketed asfood or drink attached with an indication that the food or drink is usedfor inhibiting visceral fat accumulation, for example, “food or drinkcontaining a compound having an effect of inhibiting visceral fataccumulation indicated as ‘For inhibiting visceral fat accumulation’”,or “food or drink containing a plant extract indicated as ‘Forinhibiting visceral fat accumulation’” and the like. In addition,because the compound of the present invention or the composition or thelike containing the same has the effect of inhibiting visceral fataccumulation, the indication that the food or drink is for inhibitingvisceral fat accumulation may also have a meaning of ameliorating thevisceral fat type obesity. Therefore, the food or drink of the presentinvention can also be indicated as “For ameliorating visceral fat typeobesity”. In other words, the aforementioned indication that food ordrink is for inhibiting visceral fat accumulation may be replaced by theindication of “For ameliorating visceral fat type obesity”.

The wording used for such an indication as mentioned above is notlimited to the wording “For inhibiting visceral fat accumulation” or“For ameliorating visceral fat type obesity”, and there is no need tosay that other wordings are encompassed within the scope of the presentinvention so long as the wordings indicate the effect of inhibiting thevisceral fat accumulation, or preventing or ameliorating the visceralfat type obesity. As such a wording, for example, an indication based onvarious uses allowing consumers to recognize the effect of inhibitingvisceral fat accumulation or ameliorating the visceral fat type obesityis also possible. Examples of the indication include “suitable for aperson who began to worry about waist size”, “suitable for a person whotend to be visceral fat type obesity”, and “useful for reducing orremoving risk factors (risks) of metabolic syndrome”.

The aforementioned term “indication” includes all actions for informingconsumers the aforementioned use, and any indications reminding oranalogizing the aforementioned use fall within the scope of the“indication” of the present invention regardless of purpose, content,objective article, medium etc. of the indication. However, theindication is preferably made with an expression that allows consumersto directly recognize the aforementioned use. Specific examples includeactions of indicating the aforementioned use on goods or packages ofgoods relating to the food or drink of the present invention, actions ofassigning, delivering, displaying for the purpose of assigning ordelivering or importing such goods or packages of goods indicated withthe aforementioned use, displaying or distributing advertisements, pricelists or business papers relating the goods with indicating theaforementioned use, or providing information including those as contentswith indicating the aforementioned use by an electromagnetic method(Internet etc.) and so forth. On the other hand, the indication ispreferably an indication approved by the administration etc. (forexample, an indication in a form based on an approval, which isqualified on the basis of any of various legal systems provided by theadministration), and it is particularly preferably an indication onadvertisement materials at the sales spots such as packages, containers,catalogs, pamphlets and POPs, others documents and so forth.

Examples of the indication further include indications as health food,functional food, enteric nutritive food, food for special dietary uses,food with nutrient function claims, quasi-drug and so forth as well asindications approved by the Ministry of Health, Labor and Welfare, forexample, indications approved on the basis of the system of food forspecified health uses and similar systems. Examples of the latterinclude indications as food for specified health uses, indications asfood for specified health uses with qualified health claims, indicationsof influence on body structures and functions, indications of reductionof disease risk claims and so forth, and more precisely, typicalexamples include indications as food for specified health uses(especially indications of use for health) provided in the enforcementregulations of Health Promotion Law (Japan Ministry of Health, Labor andWelfare, Ministerial ordinance No. 86, Apr. 30, 2003) and similarindications.

The present invention will be explained more specifically with referenceto the following examples. However, the scope of the present inventionis not limited to the following examples.

First, Preparation Example describes that the compound of the presentinvention or composition can be produced from a plant belonging to aLiliaceae.

PREPARATION EXAMPLE 1

In an amount of 100 kg of mesophyll (clear gel portion) of Aloe vera wasliquefied by using a homogenizer, added with 100 L of an ethylacetate/butanol mixture (3:1) and stirred.

The mixture was left standing overnight, and then the ethylacetate/butanol mixture and the aqueous layer were separated to recoverthe ethyl acetate/butanol mixture. The extract from this ethylacetate/butanol mixture obtained by concentrating the ethylacetate/butanol mixture under reduced pressure weighed 13.5 g. Asolution of 13 g of this extract dissolved in 1 mL of achloroform/methanol mixture (1:1) was loaded on a column filled with 400g of Silica Gel 60 (Merck Ltd.) to attain adsorption of the componentsto the column, then the components were eluted with achloroform/methanol mixture by the stepwise gradient method, in whichthe methanol concentration was increased stepwise (mixing ratios ofchloroform:methanol=100:1, 25:1, 10:1, 5:1 and 1:1), and the eluate wasfractionated for each mixing ratio of the aforementioned mixture. It wasconfirmed by normal phase and reverse phase thin layer chromatography(Merck Ltd., Silica Gel 60F254 and R^(P)-18F2543) that, among thesefractions, the compound of the present invention existed in the fractioneluted with the mixture of chloroform:methanol=25:1.

This crude purified substance (crude purification product 1) containingthe compound of the present invention weighed 3 g. Further, the yieldsof the crude purification products obtained in the above operation fromthe fractions eluted with the mixtures of chloroform:methanol=10:1 and1:1 were 1.17 and 2.27 g, respectively. The solvents of these fractionswere removed, then each extract was dissolved in 1 mL of achloroform/methanol mixture (1:1) and loaded on a column filled with 100g of Silica Gel 60 to attain adsorption of the components to the column,and then the components were eluted with 1100 mL of a hexane/ethylacetate mixture (4:1). The eluted fractions were collected as aliquotsof 300 mL (fraction A), 300 mL (fraction B) and 500 mL (fraction C) inthis order. The yields obtained after removing the solvents from thefractions A, B and C were 0.6 g, 1.35 g and 0.15 g, respectively. It wasconfirmed by normal phase and reverse phase thin layer chromatographythat the compound of the present invention had been concentrated in thefraction A (crude purification product 2). This crude purificationproduct 2 was further separated by HPLC using COSMOSIL C18 (NacalaiTesque, Inc.) with a chloroform/hexane mixture (85:15) to obtain 1.3 mgof compound 3 (4-methylcholest-7-en-3-ol), 1.2 mg of compound 4(4-methylergost-7-en-3-ol) and 1 mg of compound 5(4-methylstigmast-7-en-3-ol). The structures of these compounds wereconfirmed by MS and NMR.

EXAMPLE 1

In Example 1, an inhibitory effect of a compound having a lophenolskeleton on visceral fat accumulation was investigated by using ZDF(Zucker Diabetic Fatty) rats that are model animals for obese diabetes.

(1) Preparation of Samples

Compound 3 (4-methylcholest-7-en-3-ol), Compound 4(4-methylergost-7-en-3-ol), and Compound 5 (4-methylstigmast-7-en-3-ol)which were produced in Preparation Example 1 were used as Test Samples1, 2, and 3, respectively. Each of the test samples was dissolved inDMSO, and a concentration of each of the compounds in each of the testsamples was adjusted with distilled water to be 10 μg/ml, therebypreparing Test Samples 1-1, 2-1, and 3-1. Test Samples 1-2, 2-2, and 3-2each having the concentration of a compound of 1 μg/ml were prepared. Inaddition, final concentration of DMSO was adjusted to 0.2%. Further, asolution without the test samples was prepared as a negative sample.

(2) Test Method

6-week-old male ZDF rats (purchased from Charles River Laboratories,Inc., US) were preliminarily fed with a high fat diet (Research DietInc.) for 1 month, and the rats were then divided into groups of 6 ratseach. The groups of rats were orally administered with 1 ml of solutionsof the negative sample, Test Samples 1-1, 1-2, 2-1, 2-2, 3-1, and 3-2,respectively, per 400 g of body weight of a rat once a day successivelyfor 44 days by using a sonde. At 45th day from initiation of theadministration, mesenteric fat weights were measured as the visceralfat.

(3) Test Results

Table 1 shows the mesenteric fat weights at the 45th day from theinitiation of the administration. The group of rats administered withthe negative sample had a mesenteric fat weight of 6.83±1.10 g, and thegroups administered with Test Samples 1-1, 2-1, and 3-1 each having acompound concentration of 10 μg/ml, respectively, had the mesenteric fatweights of 4.48±1.34 g, 3.78±0.26 g, and 3.36±1.67 g, the fat weightsbeing 65.0%, 54.9%, and 48.7% of that of the group administered with thenegative sample. Therefore, it was confirmed that Test Samples 1-1, 2-1,and 3-1 had significant effects of inhibiting visceral fat accumulation.On the other hand, the administration of Test Samples 1-2, 2-2, and 3-2each having a compound concentration of 1 μg/ml, respectively, resultedin tendency to reduce the visceral fat, but no significant effect wasobserved. Furthermore, there was no side effects observed frompathologic viewpoints. In addition, p values in Table 1 indicatesignificance probability by Tukey-Kramer's test.

TABLE 1 Sample (concentration of Mesenteric fat active ingredient)weight (g) p value Test Sample 1-1 (10 μg/ml)  4.48 ± 1.34* 0.0380 TestSample 1-2  (1 μg/ml) 5.63 ± 1.25 0.3150 Test Sample 2-1 (10 μg/ml) 3.78 ± 0.26* 0.00004 Test Sample 2-2  (1 μg/ml) 5.74 ± 1.57 0.3332 TestSample 3-1 (10 μg/ml)  3.36 ± 1.67* 0.0002 Test Sample 3-2  (1 μg/ml)6.10 ± 1.67 0.5019 Negative sample 6.89 ± 0.61 — In the Table, “*”indicates that there was a statistically significant effect ofinhibiting visceral fat accumulation.

EXAMPLE 2

In Example 2, an effect of the compound having lophenol skeleton on anamount of food ingestion (amount of food consumption) and an increase inbody weight (amount of increased body weight) of rats was investigated.

(1) Preparation of Samples

Test Samples 1-1, 2-1, and 3-1 which were used in Example 1 were used astest samples. In addition, a solution without the test samples wasprepared as a negative sample.

(2) Test Method

6-week-old male ZDF rats (purchased from Charles River Laboratories,Inc., US) were preliminarily fed with a high fat diet (Research DietInc.) for 1 month, and body weights of the rats were measured and therats were then divided into groups of 6 rats each. The groups of ratswere orally administered with 1 ml of solutions of Test Samples 1-1,2-1, and, 3-1 and the negative sample, respectively, per 400 g of bodyweight of a rat once a day successively for 44 days by using a sonde. 42days after initiation of the administration, the body weights of therats were measured, and differences between the body weights on the 42ndday and those measured before the initiation of the administration wereregarded as amounts of increased body weights. In addition, weights offood consumed per day were measured about once a week from the day ofthe initiation of the administration, and an average of the weights wasregarded as an amount of food consumption per day.

(3) Test Results

Table 2 shows the amounts of food consumption per day and amounts ofincreased body weight during 42 days per rat. It was observed that thegroups administered with Test Samples 1-1, 2-1, and 3-1, respectively,did not show significant increase or decrease in amount of foodconsumption as compared with the group administered with the negativesample. In addition, the amounts of increased body weight (increases inbody weight) of the groups administered with Test Samples 1-1, 2-1, and3-1, respectively, were almost the same as that of the groupadministered with the negative sample. Thus, it was found that thecompound having a lophenol skeleton does not affect the amount of foodingestion and increase in body weight of rats.

TABLE 2 Amount of food Increased body Sample consumption (g) weight (g)Test Sample 1-1 21.7 ± 2.0 137.7 ± 10.8 Test Sample 2-1 21.7 ± 2.2 128.7± 14.5 Test Sample 3-1 21.4 ± 1.3 152.7 ± 28.1 Negative sample 22.5 ±1.2 140.7 ± 18.8

INDUSTRIAL APPLICABILITY

According to the present invention, there can be provided an agent forinhibiting visceral fat accumulation, which is capable of maintaining astandard body weight without decreasing the body weight, and iseffective for inhibiting progression of obesity without excessive dietrestriction or the like, and a physiologically functional food or drinksuch as food for specified health uses containing the agent forinhibiting visceral fat accumulation. Thus, diseases, complications, andthe like caused by the visceral fat accumulation, such as abnormal lipidmetabolism and cardiovascular diseases can be ameliorated or prevented,and risks of those diseases, complications, and the like can also bereduced. In addition, the present invention also provides an effect ofpreventing onset of metabolic syndrome and lifestyle-related diseaseswhich are indicated as risk factors of metabolic syndrome, such asdiabetes, hypertension, and hyperlipidemia.

1. An agent for inhibiting visceral fat accumulation, which comprises acompound represented by the following general formula (1) as an activeingredient:

(wherein, R1 represents an alkyl group, or an alkenyl group having 1 or2 double bonds, or a substituted alkyl or alkenyl group having ahydroxyl group and/or a carbonyl group, which is straight or branchedchain having 5 to 16 carbon atoms, R2 and R3 each independentlyrepresent a hydrogen atom, an alkyl group or a substituted alkyl grouphaving 1 to 3 carbon atoms, and R4 forms C═O with the carbon atomconstituting the ring or represents —OH or —OCOCH₃.
 2. The agent forinhibiting visceral fat accumulation according to claim 1, wherein oneof R2 and R3 is a hydrogen atom, the other is a methyl group, and R4 isa hydroxyl group.
 3. The agent for inhibiting visceral fat accumulationaccording to claim 2, wherein R1 is represented by any one of thefollowing formulas:—CH₂—CH₂—CH(—CH₂—CH₃)—CH(CH₃)₂;—CH₂—CH₂—CH═C(CH₃)₂;—CH₂—CH═C(CH₃)—CH(CH₃)₂;—CH₂—CH₂—C(═CH—CH₃)—CH(CH₃)₂;—CH₂—CH₂—CH(R^(a))═C(CH₃)Rb wherein R^(a) and Rb are any of —H, —OH, or—CH₃; and—CH₂—CH₂—CH(Rc)—CH(CH₃)Rd wherein R^(c) and R^(d) are any of —H, —OH, or—CH₃.
 4. The agent for inhibiting visceral fat accumulation according toclaim 3, wherein the compound is selected from the group consisting of4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol, and4-methylstigmast-7-en-3-ol.
 5. The agent for inhibiting visceral fataccumulation according to any one of claims 1 to 4, which comprises atleast 0.001% by mass of the compound.
 6. An agent for inhibitingvisceral fat accumulation, comprising an organic solvent extract or ahot water extract of a Liliaceae plant, or a fraction thereof comprisinga compound represented by the following general formula (1), wherein theorganic solvent extract or the hot water extract of the aforementionedLiliaceae plant, or the fraction thereof comprises a composition as anactive ingredient comprising at least 0.001% by dry mass of the compoundrepresented by the following general formula (1):

wherein, R1 represents an alkyl group, or an alkenyl group having 1 or 2double bonds, or a substituted alkyl or alkenyl group having a hydroxylgroup and/or a carbonyl group, which is straight or branched chainhaving 5 to 16 carbon atoms, R2 and R3 each independently represent ahydrogen atom, an alkyl group or a substituted alkyl group having 1 to 3carbon atoms, and R4 forms C═O with the carbon atom constituting thering or represents —OH or —OCOCH₃.
 7. The agent for inhibiting visceralfat accumulation according to claim 6, wherein one of R2 and R3 is ahydrogen atom, the other is a methyl group, and R4 is a hydroxyl group.8. The agent for inhibiting visceral fat accumulation according to claim7, wherein R1 is represented by any one of the following formulas:—CH₂—CH₂—CH(—CH₂—CH₃)—CH(CH₃)₂;—CH₂—CH₂—CH═C(CH₃)₂;—CH₂—CH═C(CH₃)—CH(CH₃)₂;—CH₂—CH₂—C(═CH—CH₃)—CH(CH₃)₂;—CH₂—CH₂—CH(R^(a))═C(CH₃)Rb wherein Ra and Rb are any of —H, —OH, or—CH₃; and—CH₂—CH₂—CH(Rc)—CH(CH₃)Rd wherein Rc and Rd are any of —H, —OH, or —CH₃.9. The agent for inhibiting visceral fat accumulation according to claim8, wherein the compound is selected from the group consisting of4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol, and4-methylstigmast-7-en-3-ol.
 10. A Food or drink comprising the agent forinhibiting visceral fat accumulation according to any one of claims 1 to4 and 6 to
 9. 11. The food or drink according to claim 10, whichcomprises at least 0.0001% by mass of the compound represented by theaforementioned general formula (1).
 12. (canceled)
 13. (canceled) 14.(canceled)
 15. (canceled)
 16. A method of inhibiting visceral fataccumulation, which comprises administering a compound represented bythe following general formula (1), or an organic solvent extract or hotwater extract of a Liliaceae plant, or a fraction thereof, whichcomprises at least 0.001% by dry mass of the compound, to a subjectwhose visceral fat accumulation is to be inhibited:

wherein, R1 represents an alkyl group, or an alkenyl group having 1 or 2double bonds, or a substituted alkyl or alkenyl group having a hydroxylgroup and/or a carbonyl group, which is straight or branched chainhaving 5 to 16 carbon atoms. R2 and R3 each independently represent ahydrogen atom, an alkyl group or a substituted alkyl group having 1 to 3carbon atoms, and R4 forms C═O with the carbon atom constituting thering or represents —OH or —OCOCH₃.
 17. The method according to claim 16,wherein one of R2 and R3 is a hydrogen atom, the other is a methylgroup, and R4 is a hydroxyl group.
 18. The method according to claim 17,wherein R1 is represented by any one of the following formulas:—CH₂—CH₂—CH(—CH₂—CH₃)—CH(CH₃)₂;—CH₂—CH₂—CH═C(CH₃)₂;—CH₂—CH═C(CH₃)—CH(CH₃)₂;—CH₂—CH₂—C(═CH—CH₃)—CH(CH₃)₂;—CH₂—CH₂—CH(Ra)═C(CH₃)Rb (wherein Ra and Rb are any of —H, —OH, or—CH₃); and—CH₂—CH₂—CH(R^(c))—CH(CH₃)Rd (wherein Rc and Rd are any of —H, —OH, or—CH₃.
 19. The method according to claim 18, wherein the compound isselected from the group consisting of 4-methylcholest-7-en-3-ol,4-methylergost-7-en-3-ol, and 4-methylstigmast-7-en-3-ol.